US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

2025-05-08 16:15:00 ET

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry .

However, the sector is seeing a resurgence of optimism in 2025, driven by encouraging research, drug trials and anticipated government backing.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

For further details see: